EMA/468097/2023

European Medicines Agency decision

P/0396/2023

of 27 October 2023

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP02-13-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0396/2023

of 27 October 2023

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMEA-001501-PIP02-13-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0192/2014 issued on 6 August 2014, the decision P/0160/2015 issued on 13 July 2015, the decision P/0021/2017 issued on 3 February 2017, the decision P/0304/2018 issued on 12 September 2018, the decision P/0011/2020 issued on 6 January 2020, the decision P/0404/2020 issued on 22 October 2020 and the decision P/0039/2022 issued on 31 January 2022,

Having regard to the application submitted by Sanofi Winthrop Industrie on 29 May 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 September 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dupilumab (Dupixent), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0169/2014 issued on 8 July 2014, including subsequent modifications thereof.

Article 3

This decision is addressed to Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 – Gentilly, France.

EMA/PDCO/269123/2023
Amsterdam, 8 September 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001501-PIP02-13-M08

Scope of the application

Active substance(s):

Dupilumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of asthma

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Sanofi Winthrop Industrie

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Sanofi Winthrop Industrie submitted to the European Medicines Agency on 29 May 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0192/2014 issued on 6 August 2014, the decision P/0160/2015 issued on 13 July 2015, the decision P/0021/2017 issued on 3 February 2017, the decision P/0304/2018 issued on 12 September 2018, the decision P/0011/2020 issued on 6 January 2020, the decision P/0404/2020 issued on 22 October 2020 and the decision P/0039/2022 issued on 31 January 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 10 July 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion;

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of asthma

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of asthma

2.1.1. Indication(s) targeted by the PIP

- Treatment of persistent asthma in paediatric patients 6 to less than 18 years of age that is inadequately controlled with medium to high doses of inhaled corticosteroids and a second controller medication
- Treatment of children 2 years to less than 6 years of age with recurrent severe asthmatic wheezing uncontrolled by inhaled corticosteroids

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Study removed during procedure EMEA-001501-PIP02-13-M07
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Open-label study to characterize the safety and pharmacokinetics (PK) of a single administration of dupilumab in paediatric patients 6 years to less than 18 years of age (R668-AD-1412)

	Study 3 Randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and long term safety of dupilumab in adolescent (and in adult) patients with inadequately controlled asthma [EFC13579 (QUEST study)] **Study 4** Study removed during procedure EMEA-001501-PIP02-M01 **Study 5** Study to evaluate the Safety, Pharmacokinetics (PK) and Efficacy of dupilumab in patients, 6 months to less than 6 years of age, with severe Atopic Dermatitis (AD) (R668-AD-1539) **Study 6** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in children 6 to less than 12 years old with persistent uncontrolled asthma [EFC14153 (VOYAGE study)] **Study 7** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in children 2 years to less than 6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze (EFC14771) **Study 8** Open-label follow-up study to evaluate the long-term safety and tolerability of dupilumab in adolescent (and in adult) patients who participated in previous dupilumab asthma clinical studies [LTS12551 (TRAVERSE study)] **Study 9** Open-label follow-up study to evaluate the long-term safety and tolerability of dupilumab in children 6 years to less than 12 years patients who participated in previous dupilumab asthma clinical studies [LTS14424 (EXCURSION study)]
Extrapolation, modelling and simulation studies	**Study 10** Study removed during procedure EMEA-001501-PIP02-13-M08
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of atopic dermatitis

Authorised indication(s):

- *Adults and adolescents*

  Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure

- *Children 6 months to 11 years of age*

  Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.

  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure

2. Treatment of asthma

- *Adults and adolescents*

Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment.

- *Children 6 to 11 years of age*

Dupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure

3. Treatment of Chronic rhinosinusitis with nasal polyposis (CRSwNP)

- Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure

4. Prurigo Nodularis (PN)

- Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.
  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure

5. Eosinophilic esophagitis (EoE)

- Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy (see section 5.1).
  - Invented name(s): Dupixent
  - Authorised pharmaceutical form(s): Solution for injection
  - Authorised route(s) of administration: Subcutaneous
  - Authorised via centralised procedure